BRISTOL MYERS SQUIBB CO
Fiscal years labelled by the calendar year in which they end. Bars in $ billions; per-share figures as reported.
CAPITALIZATION 12/31/25
| ($ millions) | Amount | % |
|---|---|---|
| Total debt | 47,088 | 71.8 |
| Stockholders' equity | 18,473 | 28.2 |
| Total capitalization | 65,561 | 100.0 |
2,042,714,656 shares outstanding at 22 July 2026 (cover page of the 10-Q filed 30 July 2026).
LONG-TERM DEBT 12/31/25
| ($ millions) | Amount |
|---|---|
| Long-term debt, incl. current maturities | 44,827 |
| Long-term debt, noncurrent | 42,850 |
| Current maturities | 1,977 |
| Short-term borrowings / commercial paper | 2,261 |
CAPITAL STOCK 12/31/25
| Common shares authorized | 4,500,000,000 |
| Common shares issued | 2,900,000,000 |
| Treasury shares | 887,000,000 |
| Par or stated value per share ($) | 0.1 |
| Preferred stock ($ millions) | 0 |
| Outstanding at 7/22/26 | 2,042,714,656 |
DIVIDENDS DECLARED/PAID
| Fiscal year | Per share $ | Payout % |
|---|---|---|
| 2025 | 2.49 | 72.0 |
| 2024 | 2.42 | – |
| 2023 | 2.31 | 59.8 |
| 2022 | 2.19 | 74.2 |
| 2021 | 2.01 | 64.4 |
HISTORY AND BUSINESS
HISTORY: Incorporated in Delaware.
BUSINESS: Classified by the SEC under Standard Industrial Classification 2834, Pharmaceutical Preparations. Large accelerated filer. Principal executive office: Route 206 And Province Line Road, Princeton, NJ 08543. Fiscal year ends December 31. For a description of the business, see Item 1 of the latest 10-K.
CONSOLIDATED INCOME ACCOUNT, YEARS ENDED
| ($ millions) | 12/31/25 | 12/31/24 | 12/31/23 |
|---|---|---|---|
| Revenues | 48,194 | 48,300 | 45,006 |
| Cost of revenues | 13,936 | 13,968 | 10,693 |
| Research and development | 9,951 | 11,159 | 9,299 |
| Selling, general and administrative | 7,267 | 8,414 | 7,772 |
| Depreciation and amortization | 4,011 | 9,600 | 9,760 |
| Interest expense | 1,891 | 1,947 | 1,166 |
| Income before income taxes | 9,328 | (8,379) | 8,440 |
| Income taxes | 2,272 | 554 | 400 |
| Net income | 7,054 | (8,948) | 8,025 |
| Earned per share, diluted ($) | 3.46 | (4.41) | 3.86 |
| Dividends per share ($) | 2.49 | 2.42 | 2.31 |
CONSOLIDATED BALANCE SHEET
| ($ millions) | 12/31/25 | 12/31/24 |
|---|---|---|
| Cash and equivalents | 10,209 | 10,346 |
| Receivables, net | 9,592 | 9,012 |
| Inventories | 2,690 | 2,557 |
| Total current assets | 29,390 | 29,780 |
| Property, plant and equipment, net | 7,543 | 7,136 |
| Goodwill | 21,754 | 21,719 |
| Total assets | 90,038 | 92,603 |
| Total current liabilities | 23,417 | 23,774 |
| Long-term debt | 42,850 | 47,603 |
| Total liabilities | 71,533 | 76,215 |
| Stockholders' equity | 18,473 | 16,335 |
| Total liabilities and equity | 90,038 | 92,603 |
TEN-YEAR STATISTICS: FISCAL YEARS ($ millions except per share)
| Fiscal year ended | Revenues | Oper. income | Net income | Net margin % | EPS diluted $ | Div. per share $ | Oper. cash flow | Capital expend. | Free cash flow | Total assets | Total liabilities | Total debt | Stockholders' equity | ROE % | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12/31/25 | 48,194 | – | 7,054 | 14.6 | 3.46 | 2.49 | 14,156 | 1,311 | 12,845 | 90,038 | 71,533 | 47,088 | 18,473 | 38.2 | 2.55 |
| 12/31/24 | 48,300 | – | (8,948) | -18.5 | (4.41) | 2.42 | 15,190 | 1,248 | 13,942 | 92,603 | 76,215 | 51,477 | 16,335 | -54.8 | 3.15 |
| 12/31/23 | 45,006 | – | 8,025 | 17.8 | 3.86 | 2.31 | 13,860 | 1,209 | 12,651 | 95,159 | 65,674 | 42,645 | 29,430 | 27.3 | 1.45 |
| 12/31/22 | 46,159 | – | 6,327 | 13.7 | 2.95 | 2.19 | 13,066 | 1,118 | 11,948 | 96,820 | 65,702 | 43,217 | 31,061 | 20.4 | 1.39 |
| 12/31/21 | 46,385 | – | 6,994 | 15.1 | 3.12 | 2.01 | 16,207 | 973 | 15,234 | 109,314 | 73,308 | 49,317 | 35,946 | 19.5 | 1.37 |
| 12/31/20 | 42,518 | – | (9,015) | -21.2 | (3.99) | 1.84 | 14,052 | 753 | 13,299 | 118,481 | 80,599 | 52,676 | 37,822 | -23.8 | 1.39 |
| 12/31/19 | 26,145 | – | 3,439 | 13.2 | 2.01 | 1.68 | 8,210 | 836 | 7,374 | 129,944 | 78,246 | 49,496 | 51,598 | 6.7 | 0.96 |
| 12/31/18 | 22,561 | – | 4,920 | 21.8 | 3.01 | 1.61 | 7,066 | 951 | 6,115 | 34,986 | 20,859 | 8,598 | 14,031 | 35.1 | 0.61 |
| 12/31/17 | 20,776 | – | 1,007 | 4.8 | 0.61 | 1.57 | 5,275 | 1,055 | 4,220 | 33,551 | 21,704 | 7,962 | 11,741 | 8.6 | 0.68 |
| 12/31/16 | 19,427 | – | 4,457 | 22.9 | 2.65 | 1.53 | 3,058 | 1,215 | 1,843 | 33,707 | 17,360 | 6,574 | 16,177 | 27.6 | 0.41 |
Net margin = net income ÷ revenues; ROE = net income ÷ year-end stockholders’ equity; total debt = long-term debt including current maturities plus short-term borrowings/commercial paper, as tagged in XBRL; free cash flow = operating cash flow − purchases of property, plant and equipment; d = derived as total assets − total equity where the filing does not tag total liabilities; – = not reported in XBRL for that year.
REGISTRANT:
BRISTOL MYERS SQUIBB CO
CIK 14272 · EIN 22-0790350
PRINCIPAL OFFICE:
Route 206 And Province Line Road, Princeton, NJ 08543
Tel.: 6092524621
INCORPORATED:
Delaware
INDUSTRY (SEC SIC CODE):
2834 · Pharmaceutical Preparations
FILER STATUS:
Large accelerated filer
LATEST ANNUAL REPORT:
10-K for period ended 12/31/25, filed 11 February 2026
Sources: SEC XBRL company facts (all financial figures) · SEC submissions (registrant, address, SIC, filings) · annual reports: 10-K FY2025 (filed 2/11/26) · 10-K FY2024 (filed 2/12/25) · 10-K FY2023 (filed 2/13/24) · 10-K FY2022 (filed 2/14/23) · 10-K FY2021 (filed 2/9/22) · 10-K FY2020 (filed 2/10/21) · 10-K FY2019 (filed 2/24/20) · 10-K FY2018 (filed 2/25/19). Values are the latest figures filed for each fiscal year (restated where a later 10-K restated them). Ratios and free cash flow are Pathos calculations from those figures. Retrieved 31 October 2026.
Data from SEC filings. © 2026 Pathos Investments · pathosinvestments.com · For educational purposes only. Not investment advice.